Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Real-time
Euronext Paris
04:34:39 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 217.80 EUR | +0.65% |
|
+4.71% | +3.71% |
| 10-09 | AlphaValue/Baader Europe Sees 'Stronger' Growth for Sartorius Stedim Biotech in Midterm | MT |
| 10-08 | AlphaValue's positive view is not enough for Sartorius Stedim Biotech |  |
| Market Cap | 21.05B 23.42B 19.65B 17.81B 33.43B 2,229B 33.64B 236B 92.07B 1,157B 87.92B 86.02B 3,720B | P/E 2026 * |
55.5x | P/E 2027 * | 42.8x |
|---|---|---|---|---|---|
| Enterprise Value | 23.07B 25.65B 21.52B 19.51B 36.63B 2,441B 36.85B 258B 101B 1,267B 96.32B 94.23B 4,075B | EV / Sales 2026 * |
7.36x | EV / Sales 2027 * | 6.56x |
| Free-Float |
28.47% | Yield 2026 * |
0.38% | Yield 2027 * | 0.47% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
CBOE
| 0NK7 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
Xetra
| 56S1 | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +0.65% | ||
| 1 week | +4.71% | ||
| Current month | +2.35% | ||
| 1 month | +14.63% | ||
| 3 months | +15.24% | ||
| 6 months | +18.56% | ||
| Current year | +3.71% |
| 1 week | 209.4 |  | 221.2 |
| 1 month | 189.3 | | 225 |
| Current year | 150 | | 225 |
| 1 year | 150 | | 225 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 2023-03-27 |
| Chief Tech/Sci/R&D Officer | 61 | 2011-09-07 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2015-04-06 | |
Susan Dexter
BRD | Director/Board Member | 70 | 2015-04-06 |
Lothar Kappich
BRD | Director/Board Member | 69 | 2017-09-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.65% | +4.71% | +17.13% | +15.48% | 23.42B | |
| +0.35% | +4.29% | -22.74% | +13.32% | 178B | |
| +1.31% | +10.20% | -2.39% | +30.95% | 121B | |
| -0.33% | +2.26% | -23.89% | +9.21% | 108B | |
| +0.54% | +4.13% | -44.89% | -10.10% | 75.7B | |
| +1.84% | +5.96% | +5.74% | +77.89% | 64.15B | |
| -1.75% | -0.28% | +16.15% | +64.07% | 53.49B | |
| +0.81% | +4.85% | +0.28% | -26.98% | 51.45B | |
| +1.67% | +4.41% | -16.94% | +24.13% | 41.68B | |
| -1.87% | -0.98% | +26.07% | +9.56% | 31.5B | |
| Average | +0.32% | +3.03% | -4.55% | +20.75% | 74.81B | |
| Weighted average by Cap. | +0.42% | +4.04% | -11.44% | +20.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.48B 2.92B 2.65B 4.97B 332B 5.01B 35.09B 13.7B 172B 13.08B 12.8B 554B | 3.48B 3.87B 3.25B 2.94B 5.52B 368B 5.56B 38.96B 15.21B 191B 14.53B 14.21B 615B |
| Net income | 377M 420M 352M 319M 599M 39.95B 603M 4.23B 1.65B 20.73B 1.58B 1.54B 66.68B | 483M 537M 451M 408M 767M 51.1B 771M 5.41B 2.11B 26.52B 2.02B 1.97B 85.3B |
| Net Debt | 2.01B 2.24B 1.88B 1.7B 3.19B 213B 3.21B 22.52B 8.79B 110B 8.4B 8.21B 355B | 1.76B 1.96B 1.65B 1.49B 2.8B 187B 2.82B 19.75B 7.71B 96.89B 7.36B 7.21B 312B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-15 | €217.80 | +0.65% | 4,136 |
| 26-10-14 | €216.40 | +1.31% | 100,156 |
| 26-10-13 | €213.60 | +0.38% | 76,898 |
| 26-10-12 | €212.80 | 0.00% | 45,593 |
| 26-10-09 | €212.80 | +2.31% | 75,552 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
